Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Apr;15(2):551-8.
doi: 10.1208/s12248-013-9464-8. Epub 2013 Feb 14.

Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies

Kenneth T Luu  1 , Eugenia Kraynov, Bing Kuang, Paolo Vicini, Wei-Zhu Zhong
Affiliations
Review

Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies

Kenneth T Luu et al. AAPS J. 2013 Apr.

Abstract

The industry-wide biopharmaceutical (i.e., biologic, biotherapeutic) pipeline has been growing at an astonishing rate over the last decade with the proportion of approved new biological entities to new chemical entities on the rise. As biopharmaceuticals appear to be growing in complexity in terms of their structure and mechanism of action, so are interpretation, analysis, and prediction of their quantitative pharmacology. We present here a modeling and simulation (M&S) framework for the successful preclinical development of monoclonal antibodies (as an illustrative example of biopharmaceuticals) and discuss M&S strategies for its implementation. Critical activities during early discovery, lead optimization, and the selection of starting doses for the first-in-human study are discussed in the context of pharmacokinetic-pharmacodynamic (PKPD) and M&S. It was shown that these stages of preclinical development are and should be reliant on M&S activities including systems biology (SB), systems pharmacology (SP), and translational pharmacology (TP). SB, SP, and TP provide an integrated and rationalized framework for decision making during the preclinical development phase. In addition, they provide increased target and systems understanding, describe and interpret data generated in vitro and in vivo, predict human PKPD, and provide a rationalized approach to designing the first-in-human study.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Summary of the model-based preclinical development framework for biopharmaceuticals. Boxes with dotted lines represent modeling and simulation specific activities ideally implemented during preclinical development
Fig. 2
Fig. 2
General scheme of target-mediated drug disposition (TMDD) assuming the target is localized in the tissue compartment
Fig. 3
Fig. 3
Sensitivity analysis of the effect of target concentration on the PK profile of a hypothetical antibody exhibiting TMDD. See text for parameter values used in the simulation
See this image and copyright information in PMC

References

    1. Nagle PC, Nicita CA, Gerdes LA, Schmeichel CJ. Characteristics of and trends in the late-stage biopharmaceutical pipeline. Am J Manag Care. 2008;14(4):226–9. - PubMed
    1. Sheridan C. Fresh from the biologic pipeline-2009. Nat Biotechnol. 2010;28(4):307–10. doi: 10.1038/nbt0410-307. - DOI - PubMed
    1. Mullard A. 2010 FDA drug approvals. Nat Rev Drug Discov. 2011;10(2):82–5. doi: 10.1038/nrd3370. - DOI - PubMed
    1. Lalonde RL, Honig P. Clinical pharmacology in the era of biotherapeutics. Clin Pharmacol Ther. 2008;84(5):533–6. doi: 10.1038/clpt.2008.182. - DOI - PubMed
    1. Nagle PC, Lugo TF, Nicita CA. Defining and characterizing the late-stage biopharmaceutical pipeline. Am J Manag Care. 2003;9(6 Suppl):S124–35. - PubMed

MeSH terms

Substances

LinkOut - more resources